title: Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome.
abstract: BACKGROUND
  The most common type of primary cutaneous T cell-lymphomas (CTCLs), which are characterised by a clonal proliferation of malignant skin-homing CD4(+) lymphocytes, is mycosis fungoides (MF) and its rare leukaemic variant Sézary syndrome (SS).
  
  
  OBJECTIVE
  Zanolimumab is a high affinity human monoclonal IgG1k antibody, targeting the CD4-molecule. It exhibits cytotoxic and antiproliferative effects and has previously shown efficacy in CTCLs.
  
  
  METHODS
  Literature and reference research was done by using Pubmed and updates of ongoing studies were taken from American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH )annual meeting abstracts.
  
  
  RESULTS
  This article gives an overview about efficacy, tolerability and safety as well as chemistry, pharmacodynamics and pharmacokinetics of zanolimumab in the treatment of CTCLs.
authors.affiliation: Charité Universitaetsmedizin Berlin, Skin Cancer Center Charite, Department of Dermatology and Allergy, Charitéplatz 1, DE-10117, Berlin, Germany.
authors.forename: Dominik Sebastian
authors.initials: DS
authors.lastname: Mestel
authors.forename: Marc
authors.initials: M
authors.lastname: Beyer
authors.forename: Markus
authors.initials: M
authors.lastname: Möbs
authors.forename: Matthias
authors.initials: M
authors.lastname: Steinhoff
authors.forename: Wolfram
authors.initials: W
authors.lastname: Sterry
authors.forename: Chalid
authors.initials: C
authors.lastname: Assaf
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015704:CD4 Antigens / Q000276:immunology*; D002986:Clinical Trials as Topic; D006801:Humans; D009182:Mycosis Fungoides / Q000628:therapy*; D011788:Quality of Life; D012751:Sezary Syndrome / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015704:CD4 Antigens; C520522:zanolimumab